Myeloproliferative Neoplasms (MPN)

Jason Harold Mendler, MD, PhD, Assistant Professor of Oncology, received his bachelor's degree, Summa Cum Laude, from Washington University in St. Louis, Missouri. He then went on to earn his PhD in Genetics and his medical degree at the University of Rochester School of Medicine and Dentistry in Rochester, New York. Prior to joining Wilmot Cancer Center, Dr. Mendler completed his residency at and served as chief resident of the University of Rochester Medical Center, Department of Medicine. Most recently, he completed a clinical fellowship in oncology at Ohio State University Medical Center

Dr. Eric Yang is currently an Associate Clinical Professor of Medicine at the Ronald Reagan University of California, Los Angeles Medical Center. He obtained his undergraduate and medical degrees at the University of Illinois at Chicago College of Medicine, and completed his internal medicine residency and cardiology fellowship at Harbor-UCLA Medical Center, where he served as chief fellow. Since joining the academic faculty at UCLA as a clinician educator in 2011, he has been involved both in the invasive and noninvasive realms of the field, serving as one of the cardiology liaisons on the

Anthony M. Hunter, MD, is an Assistant Professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine. A hematologist, Dr. Hunter specializes in treating patients with leukemia and other myeloid malignancies including myeloproliferative neoplasms, myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. Dr. Hunter holds professional memberships with American Society of Clinical Oncology, American Society of Hematology, and Society of Hematologic Oncology. Dr. Hunter received his Medical Degree from Medical College of Wisconsin in

As a physician caring for patients with acute leukemias and related disorders, I have a sustained focus on translational research in hematologic malignancies. Genomic sequencing technology revolutionized our understanding of cancer biology. My research focuses on exploring the dynamic changes of tumor immune microenvironment with clonal evolution of myeloid malignancies. Targeting inflammaging of bone marrow to impede clonal evolution is my ultimate professional goal and there by improve the survival rate for leukemia patients. My long-term goal is to develop potentially less toxic targeted

Dr. Elizabeth Bowhay-Carnes is a Texas native and passionate about serving the people of her home community. She earned her bachelors of science degree in biochemistry from the University of Texas at Austin, followed by work with the MD Anderson Cancer Center Umbilical Cord Blood Bank in Houston. She received her medical doctorate from UT Health San Antonio and completed her residency in internal medicine and fellowship in hematology and medical oncology at the UT Health Science Center. She joined UT Health San Antonio MD Anderson Cancer Center in 2016 as Director of the Adult Non-Malignant